A respiratory device that Baxter inherited through its $12.5 billion Hillrom acquisition might work a little too well, a problem that prompted the company to issue an urgent medical device correction.

A device that’s meant to clear out and expand the lungs may actually go too far, resulting in a potentially dangerous decrease in overall oxygen levels, Baxter said this week. In light of that ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

CHICAGO, July 13, 2020 /PRNewswire/ -- Global medical technology leader Hillrom (NYSE: HRC) today announced the launch of two new respiratory therapy devices: the Volara™ System, which provides ...